Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JSP191 |
Synonyms | |
Therapy Description |
JSP191 (AMG 191) is a humanized monoclonal antibody against CD117 (cKIT, SCFR), which may results in depletion of hematopoietic stem cells (Blood (2019) 134 (Supplement_1): 800). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JSP191 | AMG 191|JSP 191|JSP-191|AMG191|AMG-191 | JSP191 (AMG 191) is a humanized monoclonal antibody against CD117 (cKIT, SCFR), which may results in depletion of hematopoietic stem cells (Blood (2019) 134 (Supplement_1): 800). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04429191 | Phase I | JSP191 | JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation | Unknown status | USA | 0 |
NCT05903274 | Phase I | JSP191 | JSP191 (Briquilimab) in Subjects With LR-MDS | Recruiting | USA | 0 |